Positive News SentimentPositive NewsNASDAQ:EYEN Eyenovia (EYEN) Stock Forecast, Price & News $1.70 +0.06 (+3.66%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.65▼$1.7250-Day Range$1.57▼$2.3352-Week Range$1.50▼$5.85Volume185,966 shsAverage Volume344,975 shsMarket Capitalization$64.96 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Eyenovia MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside618.6% Upside$12.00 Price TargetShort InterestBearish3.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.67Based on 3 Articles This WeekInsider TradingAcquiring Shares$90,264 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.69) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector404th out of 963 stocksPharmaceutical Preparations Industry177th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Eyenovia has a forecasted upside of 618.6% from its current price of $1.67.Amount of Analyst CoverageEyenovia has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.82% of the outstanding shares of Eyenovia have been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Eyenovia has recently increased by 9.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYEN. Previous Next 3.7 News and Social Media Coverage News SentimentEyenovia has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eyenovia this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,264.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 16.66% of the stock of Eyenovia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($0.69) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eyenovia (NASDAQ:EYEN) StockEyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More EYEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYEN Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comEyenovia to Participate in Panel Discussion at Cantor Global Healthcare ConferenceSeptember 7, 2023 | finance.yahoo.comEyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 27, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 28, 2023 | msn.comEyenovia: It Is Now Time To See Positive Results In Their Marketing EffortsAugust 24, 2023 | finance.yahoo.comEyenovia Announces $12 Million Registered Direct OfferingAugust 18, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)August 16, 2023 | msn.comEyenovia acquires US licencing rights for Formosa’s topical eye steroidAugust 16, 2023 | markets.businessinsider.comFormosa Pharma: Eyenovia Obtains U.S. Rights For Commercialization Of APP13007September 27, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 16, 2023 | finance.yahoo.comEyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa PharmaceuticalsAugust 16, 2023 | prnewswire.comFormosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular SurgeryAugust 14, 2023 | finance.yahoo.comEyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Eyenovia (EYEN)August 11, 2023 | finance.yahoo.comQ2 2023 Eyenovia Inc Earnings CallAugust 10, 2023 | seekingalpha.comEyenovia GAAP EPS of -$0.16 beats by $0.01August 10, 2023 | msn.comCrexendo Non-GAAP EPS of $0.04 beats by $0.03, revenue of $12.7M beats by $0.87MAugust 10, 2023 | finance.yahoo.comEyenovia Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | benzinga.comEarnings Preview For EyenoviaAugust 9, 2023 | finance.yahoo.comEyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceAugust 7, 2023 | finance.yahoo.comEyenovia to Report Second Quarter 2023 Results on Thursday, August 10August 3, 2023 | finance.yahoo.comEyenovia Announces First Commercial Sale of Mydcombi™July 14, 2023 | finance.yahoo.comEYEN - Eyenovia, Inc.June 26, 2023 | finance.yahoo.comEyenovia Announces Addition to Russell 2000® and Russell 3000® IndexesJune 6, 2023 | finanznachrichten.deEyenovia, Inc.: Eyenovia Expands Its US Manufacturing CapabilitiesJune 6, 2023 | finance.yahoo.comEyenovia Expands Its US Manufacturing CapabilitiesJune 1, 2023 | finance.yahoo.comEyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023May 27, 2023 | msn.comEyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market PlaceSee More Headlines Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address EYEN Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+614.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-158.92% Return on Assets-83.86% Debt Debt-to-Equity Ratio1.25 Current Ratio5.73 Quick Ratio5.73 Sales & Book Value Annual Sales$14 million Price / Sales4.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.50Miscellaneous Outstanding Shares38,210,000Free Float35,231,000Market Cap$64.19 million OptionableNot Optionable Beta1.68 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Tsontcho Ianchulev M.D. (Age 49)M.P.H., MPH, Co-Founder & Exec. Chairman Comp: $920.87kMr. Michael M. Rowe (Age 61)CEO & Director Comp: $750.01kMr. John P. Gandolfo CPA (Age 62)CFO & Sec. Comp: $598.39kMr. Bren Kern (Age 42)COO & Corp. VP Alexander LoboInvestor ContactKey CompetitorsShattuck LabsNASDAQ:STTKAdicet BioNASDAQ:ACETSpero TherapeuticsNASDAQ:SPROXilio TherapeuticsNASDAQ:XLOAdageneNASDAQ:ADAGView All CompetitorsInsiders & InstitutionsMichael M RoweBought 1,400 shares on 9/19/2023Total: $2,324.00 ($1.66/share)Michael M RoweBought 1,137 shares on 9/15/2023Total: $1,989.75 ($1.75/share)Stuart M GrantBought 45,000 shares on 8/16/2023Total: $85,950.00 ($1.91/share)Nuveen Asset Management LLCBought 200,143 shares on 8/16/2023Ownership: 0.524%XTX Topco LtdBought 27,400 shares on 8/15/2023Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions EYEN Stock - Frequently Asked Questions Should I buy or sell Eyenovia stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EYEN shares. View EYEN analyst ratings or view top-rated stocks. What is Eyenovia's stock price forecast for 2023? 1 brokerages have issued 1 year price objectives for Eyenovia's shares. Their EYEN share price forecasts range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts. How have EYEN shares performed in 2023? Eyenovia's stock was trading at $1.63 at the beginning of 2023. Since then, EYEN shares have increased by 3.1% and is now trading at $1.68. View the best growth stocks for 2023 here. Are investors shorting Eyenovia? Eyenovia saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,460,000 shares, an increase of 9.8% from the August 31st total of 1,330,000 shares. Based on an average daily volume of 246,500 shares, the days-to-cover ratio is presently 5.9 days. View Eyenovia's Short Interest. When is Eyenovia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our EYEN earnings forecast. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS). When did Eyenovia IPO? (EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." Who are Eyenovia's major shareholders? Eyenovia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.51%), Geode Capital Management LLC (1.46%), State Street Corp (1.16%), Renaissance Technologies LLC (1.12%), Northern Trust Corp (0.62%) and Nuveen Asset Management LLC (0.53%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View institutional ownership trends. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $1.68. How much money does Eyenovia make? Eyenovia (NASDAQ:EYEN) has a market capitalization of $64.19 million and generates $14 million in revenue each year. The company earns $-28,010,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How can I contact Eyenovia? Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The official website for the company is www.eyenoviabio.com. The company can be reached via phone at (917) 289-1117 or via email at tbui@theruthgroup.com. This page (NASDAQ:EYEN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.